Member Info for Yorkshirepragma

Written as an ‘old bold’ scientist....in Avacta since pre consolidation!
Superb technology being applied at a difficult time.

Science declared thus gives a higher quality result & that’s what matters. Potential to examine stages of infection possibly also.
It’s in good hands...fear not!
Next issue making enough of the tests to deliver demand I suspect..and this no doubt in hand too.
Millions units per annum @ $5 . Significant revenue.

https://www.lifescienceleader.com/doc/how-to-overcome-the-challenge-of-valuing-a-biotech-0001

A Step ahead, but clearly a projected value would be significant with current activity.
GLA

Should it happen then it would be champagne time...don’t worry

That’s Pharms...apologies

Should a T/O eventually emerge,I’m suspect the offer would be robust. Pharos often ‘ tick up’ over book value. As MM indicated in his review, it would take away the decision too!
Onwards...

1bn? And the rest...revenue from testing royalty likely to move this forward shortly.
McNulty analysis last summary point on takeover would be good in 6 months .

Indeed substantial...@ if income ca $200m then at forward P/E of conservât 5 then co value $1m and upwards. Yes.... 5 is low for an exciting biotech.
Best wishes to all...

Whatever emerges, it’ll be likely a significant figure. The practicality of the two options signed up to date are both sound in delivery terms to the market.
One things for sure the significant revenue that may rapidly accrue here , is probably. likely to exceed current Market cap.on successful delivery.

Agreed,calc. just to illustrate a conservative position.

So if 5% of the worlds 7.5bn used a test annually, and Avacta profited from 10% of these testS then the annual revenue would be ca. $187m... @ $5 return.....ho hum

Just listening to 3rd world doctor’s description of situation ...dire. Seeking testing desperately. What a world problem, let’s hope Avacta succeed for everyone’s sake.

Once a-positive RNS emerges, market will find its own level.....certainly above last close....one day at a time....relax it’ll be fine. Great company, great research ,great products great potential .

CEO brief says as much in terms of affirmer specificity,
By the bye don’t jinx this bone with that old star name....not personal!

JR,
Yup ,thankfully not a comparable test.
Demand will be millions test a day when LFD saliva test emerges shortly.
Hold tight not an Aussie in sight!
Cheers

And therefore. Bizarre that Filta group a ‘commercial fryer ‘cleaning contractor goes top of the riser board today ( announcing a corovirus clean and associated check product) versus a techno quality company such as Avacta....not that I don’t like chips!

https://www.nytimes.com/2019/02/28/business/dealbook/pharmaceutical-biotech-acquisitions.html

Usually a premium paid for biotech.

Thanks for this sensible question. Full steam ahead then....

Thanks for this sensible question. Full steam ahead then....

Some interesting recent comments on biotech takeovers

https://www.genengnews.com/a-lists/10-takeover-targets-to-watch-in-2019/